Dezhan Healthcare Company Limited
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Dezhan Health Co., Ltd. (hereinafter referred to as Dezhan Health), formerly known as Xinjiang Tianshan Wool Textile Co., Ltd., was approved by the Foreign Investment Management Committee on June 23, 1980. It was a limited liability company established in January 1981 by a joint venture between Xinjiang Uygur Autonomous Region Urumqi Wool Textile Factory and Hong Kong Tianshan Wool Textile Co., Ltd. In March 1998, with the approval of the China Securities Regulatory Commission, it was listed on the Shenzhen Stock Exchange (stock code 000813) in May. In July 2016, it underwent a major asset restructuring and was renamed Dezhan Health Co., Ltd. Currently, Xinjiang Financial Investment Co., Ltd., a state-owned sole proprietorship directly supervised by the State owned Assets Supervision and Administration Commission of the Autonomous Region, holds a controlling stake in a state-owned listed company and is also the only pharmaceutical listed company in the Autonomous Region. The company's main business area is centered around the pharmaceutical industry, mainly engaged in the research and development, production, and sales of chemical drugs, formulations, and other industries, as well as industrial hemp, biopeptides, and other industries. The company's products cover the major health fields such as pharmaceuticals, vaccines, health products, functional beverages, cosmetics, etc. Currently, the company's total secondary market value is approximately 9 billion yuan. The company currently has 24 participating holding enterprises, including 9 secondary enterprises, 9 tertiary enterprises, 2 enterprises below tertiary level, and 4 participating enterprises. The company is composed of a shareholders' meeting, a board of directors, a supervisory board, and a manager, who respectively exercise the functions of a power body, decision-making body, supervisory body, and executive body, and operates well. The board of directors consists of 9 members, including 3 independent directors. It consists of the Strategy and Development Committee, Audit Committee, Nomination Committee, and Remuneration and Assessment Committee, with independent directors accounting for the majority of each committee member; There are 5 members of the supervisory board, including 3 employee representative supervisors. Since its establishment, the company has adhered to the concept of "innovating high-quality products and leading the forefront", attached great importance to technological innovation work and investment in technological research and development, and has achieved multiple domestically exclusive products with successful industrialization. Currently, the main products on the market involve governance drugs in the fields of cardiovascular and cerebrovascular diseases and tumors. Among them, the main product is Ale, which is one of the world's largest prescription drugs with sales, and is the first generic drug of Lipitor in China. At present, the company has four professional pharmaceutical research and development institutions, namely the Pharmaceutical Biotechnology Research Institute under Jialin Pharmaceutical, Honghui New Pharmaceutical, Deyi Pharmaceutical, and HanPeptide Biological Research Institute. It has over 200 experienced and highly educated full-time R&D personnel responsible for the technical improvement of the company's existing products and the development of new drugs. Jialin Pharmaceutical, a wholly-owned subsidiary, is a high-tech enterprise in Beijing and has been listed as one of the "Top 100 Industrial Enterprises in China's Chemical and Pharmaceutical Industry with Comprehensive Strength" and "Top 100 Pharmaceutical Industry in China" for 8 consecutive years. The company's flagship product "Ale" (atorvastatin calcium tablets) is a milestone and heavyweight product in the history of lipid-lowering drugs. It has won the "Second Prize of National Science and Technology Progress" and has been listed on the "2020 China Chemical Pharmaceutical Industry Excellent Lipid-lowering Product Brands" list for 8 consecutive times. In the future, the company and its subsidiaries will continue to be diligent in innovation, brave in exploration, and focus on the field of cardiovascular and cerebrovascular drugs. They are determined to develop into a professional pharmaceutical enterprise that integrates research and development, production, and marketing, providing high-quality and reassuring drugs for millions of patients, and safeguarding the health of the people. |
| Headquarter | Urumqi |
| Establish Date | 1/1/1981 |
| Listed Code | 000813.SZ |
| Listed Date | 5/19/1998 |
| Chairman | Wei Zheming, Liu Wei. |
| CEO | Liu Wei. |
| Website | www.dezhanhealthcare.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
